Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research: Pharma & Biotech Stocks Outpace Mkt This Yr; Firms w/ Robust Product Sales Growth Recommended
Recommend 48 Positive 63 Negative 43 |
||||
|
||||
|
The Chinese pharma and biotech sectors have outpaced the market this year, according to a report from HSBC Global Research. Driven by companies' steady product sales growth and rapid business development, the A-share pharma index rose by 23%, while the H-share innovative drug index surged by 107%, powering a continuous revaluation of the industry. HSBC Global Research suggested investors choose companies with sturdy product sales growth and rich early-stage R&D pipelines. In the pharma sector, the broker favored SINO BIOPHARM (01177.HK), HENGRUI PHARMA (01276.HK) (600276.SH), and HANSOH PHARMA (03692.HK). In the biotech sector, the broker preferred BEIGENE (06160.HK) (ONC.US) and INNOVENT BIO (01801.HK), all rated as Buy. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
